SCHEMBL1149124

SCHEMBL1149124

CC(C)(C)OC(=O)N1CCC(Oc2cc(Cl)cc3cccnc23)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNB4 O00305 2/20 0.49
CACNA1A O00555 2/20 0.49
CACNA1G O43497 2/20 0.49
CACNG3 O60359 2/20 0.49
CACNA1F O60840 2/20 0.49
CACNA1H O95180 2/20 0.49
CACNB3 P54284 2/20 0.49
CACNA2D1 P54289 2/20 0.49
CACNG7 P62955 2/20 0.49
CACNA1B Q00975 2/20 0.49
CACNA1D Q01668 2/20 0.49
CACNB1 Q02641 2/20 0.49
CACNG1 Q06432 2/20 0.49
CACNB2 Q08289 2/20 0.49
CACNA1S Q13698 2/20 0.49
CACNA1C Q13936 2/20 0.49
CACNA1E Q15878 2/20 0.49
CACNA2D4 Q7Z3S7 2/20 0.49
CACNA2D3 Q8IZS8 2/20 0.49
CACNG8 Q8WXS5 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12138360 0.94 PIK3CD (0.47) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3716533 0.90 CACNB4 (0.54) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3709887 0.89 GPR119 (0.48) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3708948 0.89 GPR119 (0.51) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3055131 0.88 GPR119 (0.47) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3805418 0.86 KDM1A (0.53) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3711289 0.86 HRH1 (0.52) PDE4APDE4BPDE4CPDE4DHRH1
SCHEMBL3715445 0.84 HRH1 (0.48) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL3718500 0.84 HRH1 (0.52) HRH1KCNH2
SCHEMBL3648875 0.83 HRH1 (0.46) GPR119HRH1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281909-A1 SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2011-11-17 US disclosed
US-7884114-B2 N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis GLAXO GROUP LIMITED (GB) 2011-02-08 US disclosed
US-20100222349-A1 QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES GLAXO GROUP LIMITED (GB) 2010-09-02 US disclosed
EP-2205585-A1 QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES Glaxo Group Limited (GB) 2010-07-14 EP disclosed
EP-2185542-A2 SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS Glaxo Group Limited (GB) 2010-05-19 EP disclosed
US-20090270355-A1 Compounds GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
WO-2009050204-A1 QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES GLAXO GROUP LIMITED (GB) 2009-04-23 WO disclosed
WO-2009021965-A2 SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270355-A1 Compounds CMA1, HRH4, CCL11 CACNB4 3573/4885CACNA1A 2134/4885CACNA1G 3637/4885
US-20100222349-A1 QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES IL5, HRH2, HRH1 CACNB4 3853/4885CACNA1A 1108/4885CACNA1G 3222/4885
US-20110281909-A1 SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS HRH1, HRH2, HRH4 CACNB4 3090/4885CACNA1A 1027/4885CACNA1G 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.